Lead Sponsor

VISUfarma SpA

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult patients (age ≥ 18)
•Naïve and pre-treated patients scheduled for IVI
•Diagnosis of one of the following:
•* ARMD
•* mCNV
•* Proliferative diabetic retinopathy
•* Diabetic macular oedema
•* Macular oedema secondary to retinal vein occlusion
•The subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent, approved by the local Ethics Committee (EC).

•Use of systemic antibiotics, corticosteroids within 3 months
•Use of topical antibiotics and or corticosteroids within 15 days from study enrolment
•Use of topical Artificial Tears within 15 days from the enrolment
•Use of topical antiseptic agents within 1 month from study enrolments
•Presence of topical ocular therapies that cannot be suspended for the entire duration of the study
•Ongoing ocular or systemic inflammatory or infectious processes
•Known hypersensitivity to the constituents of the study product
•Diagnosis of Open-Angle Glaucoma
•Uveitis
•Acute and Chronic Conjunctival Disease
•Any intraocular surgery within 6 months from study enrolment, excluded IVI
•Severe and Moderate Dry Eye
•Pregnancy or breast-feeding
•Participation in other clinical studies
•Patients with cognitive impairment and unable to manage home-assigned treatment.

Related studies

NCT07354477 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), and more

NCT06713720 · Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy, and more

NCT06951087 · Non-Proliferative Diabetic Retinopathy

NCT06582511 · Macular Degeneration, Age Related

NCT05393284 · Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy

VISUPRIME® Eye Drops